Form 4: NeoGenomics Director Michael Kelly Reports Equity Changes
Statement of Changes in Beneficial Ownership
Director Michael Kelly acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units and received new equity grants.
Summary
- Director Michael Aaron Kelly acquired 23,077 shares of common stock on June 1, 2026, via the vesting of restricted stock units (RSUs).
- Following the transaction, the director holds 67,086 shares directly and 5,000 shares indirectly through a revocable trust.
- The director was granted new equity compensation consisting of 11,069 stock options (exercise price $10.52) and 15,970 RSUs.
- The new stock options vest on June 1, 2027, and expire on June 1, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding director compensation and ownership, which carries no inherent market sentiment.
Positives
- Director maintains significant skin in the game with a total beneficial ownership of 72,086 shares.
- Equity grants align director incentives with long-term shareholder value creation.
Negatives
- None identified; this is a standard compensatory equity filing.
Risks
- None identified; this is a standard compensatory equity filing.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity transactions.
Industry Context
StockSavvy.ai notes that routine equity compensation filings for directors are standard practice in the biotechnology and diagnostics sector, reflecting typical corporate governance and retention strategies.
Comparison to Industry Standards
- The equity compensation structure is consistent with standard practices for mid-cap healthcare companies.
- The use of both RSUs and stock options is a common retention tool for board members in the diagnostic services industry.
Stakeholder Impact
- Minimal impact on shareholders as these are standard compensatory equity grants.
Next Steps
- Vesting of new equity grants on June 1, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/28/2021 | Grant date of previous stock options |
| 06/02/2022 | Grant date of previous stock options |
| 06/10/2023 | Grant date of previous stock options |
| 08/10/2024 | Grant date of previous stock options |
| 06/01/2025 | Grant date of previous stock options |
| 06/01/2026 | Transaction date for RSU vesting and new equity grants |
| 06/01/2027 | Vesting date for new stock options and RSUs |
Keywords
NeoGenomics, NEO, Form 4, Insider Trading, Director Compensation, Equity Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.